CClinicalTrials.gg
RecruitingNCT06330818IMAGINEUpdated Sep 26, 2024

Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients

An interventional study of MRI and H2 15O PET/CT in Moyamoya Disease and Moyamoya, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Aim of this study is to improve patient care in Moyamoya Patients by improving Imaging technologies and aiming to identify factors involved in disease progression.

Main tasks are:

  • Analysis of CO2-triggered BOLD fMRI for analysis of cerebral hemodynamics in comparison to H2 15O PET/CT
  • Analysis of longitudinal changes of contrast enhancement in vessel-wall imaging and correlation of disease activity with biosampling
  • Definition of a standardized recommendation for pre- and postoperative imaging of Moyamoya patients
Read the detailed description

Moyamoya Disease (MMD) is a rare disease defined by a bilateral stenosis or occlusion of the terminal internal carotid artery (ICA) and proximal arteries of the circle of willis. The stenosis is usually accompanied by fine collateral vessels appearing as "a puff of smoke" on conventional DSA giving the disease its name (Japanese). The disease is known to progress over time in 20-40% of adult patients, also to initially not affected vessels. To prevent from ischemic or hemorrhagic strokes, most patients need microsurgical revascularization with extracranial-intracranial (EC-IC) bypasses for the affected cerebrovascular territories. The indication for a possible revascularization should always be decided based on functional imaging identifying cerebrovascular territories with an insufficient reserve capacity. The "gold-standard" for measuring the cerebrovascular reserve is H2 15O PET/CT with Acetazolamide challenge (ACZ), whereat also SPECT and different MRI techniques are used but with less sensitivity. Main drawback of H2 15O PET/CT is its very limited availability, high costs, the need to inject ACZ and radiation exposure. Further, the costs of H2 15O PET/CT for Moyamoya patients are not covered by the German health insurance system as no valid high-quality studies are available to prove a possible benefit of this examination.

Throughout the last years the investigators have focused our research on different MRI techniques in Moyamoya patients aiming to find reliable examinations for the evaluation of the cerebral blood flow and to detect and monitor disease progression:

The investigators' newly developed semi-automated algorithms for the evaluation of CO2-triggered BOLD MRI (breathhold fMRI) sequences to identify a reduced vasoreactivity showed a promisingly high correlation to the results of the cerebrovascular reserve measurements as seen in PET/CT. Further, the investigators were able to show that disease progression can be predicted by a temporary contrast enhancement of the vessel wall seen over approximately 24 months as high-resolution vessel-wall imaging was performed consequently in all patients.

Therefore, the main goals of this study are to improve patient care in Moyamoya patients with the following three key elements:

  1. Defining the value of CO2 triggered BOLD MRI in the evaluation of cerebral hemodynamics pre- and postoperatively compared to H2 15O PET/CT aiming to possibly prove or reduce the need for PET/CT examinations.
  2. Understanding radiographic and pathophysiologic processes causing disease progression as seen by vessel-wall imaging to enable timely revascularization or possibly non-surgical treatment of this disease in the future.
  3. Possible new insights in disease-pathophysiology and progression as seen in vessel wall imaging by correlating imaging results with biosampling (peripheral blood
  4. Defining a standardized recommendation for pre- and postoperative hemodynamic and MR-morphologic evaluation of Moyamoya patients based on the results of this study.

As secondary objectives the following elements will be analyzed:

  1. Neuropsychological impairment in correlation to the hemodynamic and MR-morphologic status of the brain.
  2. Feasibility of resting-state fMRI to evaluate cerebral vasoreactivity.

To achieve these goals, the investigators are planning to prospectively include 50 Moyamoya patients in this study with a standardized imaging, neuropsychological testing and biosampling protocol with a two-year follow-up. Under the assumption of a homogenous inclusion of patients, recruitment should be finished after two years with one year of follow-up after the inclusion of the last patient. This cohort will provide reliable information on standardized diagnostic patterns and possibly a broader understanding of pathophysiology causing disease development and progression.

02

Conditions studied

  • Moyamoya Disease
  • Moyamoya

Browse trials for

Keywords

  • Stroke
  • Moyamoya
  • EC-IC Bypass
03

In context

Moyamoya Disease

60 studies on the registry are indexed under Moyamoya Disease; 25 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 30 interventional studies indexed under Moyamoya Disease.

Browse Moyamoya Disease studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 476 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients with suspicion of Moyamoya Disease
  • Patients able to understand the study and to give their informed consent

Exclusion criteria

Exclusion Criteria:

  • Cerebral vascular disease caused by atherosclerosis
  • Vasculitis
  • Contraindications to MRI
  • Contraindications to PET/CT
  • Pregnancy
  • Inability to give informed consent
  • Renal insufficiency
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Moyamoya patients

    Newly diagnosed Moyamoya patients who will follow a standardized imaging and biosampling protocol. Possible surgical or conservative treatment will not be influenced by this study.

    Diagnostic Test: MRI · Diagnostic Test: H2 15O PET/CT · Other: Biosampling

  • No intervention
    Control group

    Healthy patients and patients with intracerebral atherosclerotic disease are used as comparators for the results of biosampling.

Interventions

  • Diagnostic testMRI

    Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.

  • Diagnostic testH2 15O PET/CT

    Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images

  • OtherBiosampling

    Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis

06

What researchers measure

Primary outcomes

  1. Value of CO2-triggered BOLD MRI compared to PET/CT

    Analysis of comparability of fMRI-based vasoreactivity and PET/CT based vasoreserve (Signal change in percent)

    Time frame: From enrollment until maximum of 24 months

Secondary outcomes

  1. Vessel-Wall contrast enhancement

    Analysis of vessel-wall contrast enhancement as predictor for disease-activity (Intensity of contrast enhancement relative to reference tissue on MRI)

    Time frame: From enrollment until maximum of 24 months

  2. Circulating endothelial cells

    FACS-based analysis of circulating endothelial cells as indicator for disease activity (absolute number of respective circulating endothelial cells subgroup)

    Time frame: From enrollment to a maximum of 24 months

  3. PCR-based virus sampling

    Analysis of possible virus infections as indicator for disease etiology (absolute number of Virus DNA based on PCR results)

    Time frame: From enrollment until maximum 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be made available anonymized upon reasonable request

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06330818
Lead sponsor
University Hospital Tuebingen
Collaborators
University Hospital Freiburg
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Jul 1, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 26, 2024

Study contacts

Constantin Roder, Prof. Dr., MD
Contact
constantin.roder@med.uni-tuebingen.de
0049-7071290

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion